Pharma: Page 3
-
Courtesy of Vertex Pharmaceuticals
FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia
The agency’s decision to expand use of Casgevy, which won a landmark OK for sickle cell disease in December, comes two months ahead of schedule.
By Ned Pagliarulo • Jan. 16, 2024 -
Permission granted by ClinicalMind
Sponsored by ClinicalMindSimplifying speaker engagement in Pharma: A holistic approach
Relationships with Speaker Bureau faculty are among the most important that a biopharmaceutical company nurtures.
Jan. 16, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
By BioPharma Dive staff -
Brian Tucker / BioPharma Dive
The biopharma industry outlook on 2024: Guarded optimism for a rebound
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
By Ned Pagliarulo • Jan. 16, 2024 -
Mario Tama / Getty via Getty Images
FDA says no ‘clear relationship’ between GLP-1 drugs and suicide risk
Regulators will continue to evaluate suicide ideation as the data don't "definitively rule out" an association.
By Jonathan Gardner • Jan. 12, 2024 -
jetcityimage via Getty Images
5 questions facing pharma in 2024
New drugs for obesity and cancer are the focus of many pharma companies, some of which are also grappling with how to manufacture complex cell and gene therapies.
By Jonathan Gardner , Ned Pagliarulo • Jan. 10, 2024 -
Danielle Ternes / BioPharma Dive
JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense
Radiopharma drugmakers spoke with BioPharma Dive about chasing Novartis in the hot field, while Bluebird’s CEO explained the company’s sickle cell therapy pricing.
By Ben Fidler , Ned Pagliarulo , Gwendolyn Wu • Jan. 10, 2024 -
Danielle Ternes / BioPharma Dive
JPM24: Pfizer’s tough sell, the next Karuna and building a biotech platform
Albert Bourla acknowledged Pfizer’s difficult 2023, while PureTech’s Daphne Zohar spoke with BioPharma Dive about building neuroscience startups.
By Ben Fidler , Delilah Alvarado • Jan. 9, 2024 -
Warren Little via Getty Images
GSK to buy asthma drug startup Aiolos for $1B
Aiolos, which raised a Series A round three months ago, is developing an antibody that shares a target with Amgen and AstraZeneca’s Tezspire.
By Ned Pagliarulo • Jan. 9, 2024 -
Danielle Ternes / BioPharma Dive
JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job
The chip maker struck a new deal with Amgen last Monday, while Sarepta brought news of strong sales to the J.P. Morgan Healthcare Conference.
By Gwendolyn Wu , Delilah Alvarado , Ben Fidler • Jan. 8, 2024 -
Kena Betancur via Getty Images
Merck pays $680M for struggling cancer biotech Harpoon
The acquisition will build out Merck’s pipeline of immunotherapies as its top-seller Keytruda nears the end of U.S. market exclusivity.
By Jonathan Gardner • Jan. 8, 2024 -
Mario Tama via Getty Images
J&J to acquire ADC drug developer Ambrx for $2B
The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.
By Ned Pagliarulo • Jan. 8, 2024 -
hapabapa via Getty Images
Novo taps Flagship startups to develop drugs for obesity, MASH
The research deals with Omega Therapeutics and Cellarity are the first under a broad alliance Novo struck with Flagship last spring.
By Kristin Jensen • Jan. 4, 2024 -
Artur Plawgo via Getty Images
Roche joins startup Remix in bet on another way to drug RNA
The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.
By Ben Fidler • Jan. 3, 2024 -
Permission granted by Novartis
Novartis deepens ties with Voyager via $100M gene therapy deal
The deal builds on an existing alliance and includes tools Novartis will use in gene therapies for Huntington’s disease and spinal muscular atrophy.
By Delilah Alvarado • Jan. 2, 2024 -
Permission granted by Bristol-Myers Squibb
Bristol Myers to acquire brain drug developer Karuna for $14B
The deal would hand Bristol Myers, which is reprioritizing neuroscience research, an experimental treatment for schizophrenia that analysts think could become a blockbuster product.
By Ned Pagliarulo , Ben Fidler • Updated Dec. 22, 2023 -
Courtesy of Sanofi
Sanofi scraps a top ADC prospect after study setback
The drug, acquired via a deal with ImmunoGen, was the most advanced experimental medicine in the French pharma’s pipeline.
By Ben Fidler • Dec. 21, 2023 -
Warren Little via Getty Images
GSK adds to ADC dealmaking with second Chinese biotech pact
The deal with Hansoh Pharma, GSK’s second this year, gives the company an antibody-drug conjugate in testing for solid tumors like lung cancer.
By Jonathan Gardner • Dec. 20, 2023 -
Courtesy of Merck & Co.
Merck gets FDA decision date for new pneumococcal vaccine
The company’s shot targets 21 strains of pneumococcal bacteria and, if approved, would compete with Pfizer’s Prevnar 20.
By Delilah Alvarado • Dec. 19, 2023 -
Courtesy of Novo Nordisk
Foundation behind Novo Nordisk to invest $260M in vaccine R&D
The newly established initiative, which consists of a research center and an accelerator, will focus on developing vaccines for tuberculosis, influenza and group A streptococcus.
By Delilah Alvarado • Dec. 18, 2023 -
Courtesy of Novartis
Amgen finds a new top scientist in Novartis veteran Bradner
Jay Bradner, a well-known physician-scientist who left Novartis last year amid an organizational shakeup, will now serve a Amgen’s chief scientific officer and head of R&D.
By Jacob Bell • Dec. 15, 2023 -
Anna Moneymaker via Getty Images
Supreme Court to rule on abortion pill access
The court's decision on mifepristone, expected by June, could have far-reaching implications for the FDA as well as the biotechnology industry.
By Delilah Alvarado • Dec. 13, 2023 -
Drew Angerer via Getty Images
Pfizer to deepen cost cuts as latest sales forecasts miss expectations
The company is now expecting to save $4 billion by the end of 2024, with a majority of the spending cuts coming from drug research and development.
By Jonathan Gardner • Dec. 13, 2023 -
Christopher Furlong via Getty Images
AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B
The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.
By Delilah Alvarado • Dec. 12, 2023 -
Permission granted by Bristol-Myers Squibb
Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree
The lucrative alliance, potentially worth more than $8 billion, continues a run of dealmaking for a class of cancer drugs that’s surged in popularity in recent years.
By Ben Fidler • Dec. 12, 2023 -
Permission granted by Celonis
Sponsored by CelonisLife sciences leaders invest in process mining to accelerate digital transformation
Research from Everest Group shows how life sciences leaders are investing in process mining to speed time-to-market, improve regulatory compliance and drive innovation.
By Rachel Stolba • Dec. 11, 2023
Previous
